Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
>
Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms
Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms
Read also
UK and US agree on landmark pharma pricing tariff deal
The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.
Parkinson's drug as basis for new anti-infectives
Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.
Modified herpes virus helps destroy glioblastoma in preclinical models
Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.
Bayer takes Alport syndrome drug into phase 2
Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for Alport syndrome, a rare, genetic disease that leads to chronic kidne...
